Epigenomics and Cancer Risk Factors

List of publications Daniel Lipka

2016

  1. Lipka DB, Wagner MC, Dziadosz M, Fischer T. Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias. Leukemia 2016. (Epub ahead of print) Abstract Open Access
  2. Fluhr S, Boerries M, Busch H, Symeonidi A, Witte T, Lipka DB, Mucke O, Nollke P, Krombholz CF, Niemeyer CM, Plass C, Flotho C. CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia. Clin Epigenetics 2016; 8: 50. Abstract
  3. Wilhelm T*, Lipka DB*, Witte T*, Wierzbinska JA, Fluhr S, Helf M, Mücke O, Claus R, Konermann C, Nöllke P, Niemeyer CM, Flotho C, Plass C. (* Co-first author) Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia. Epigenetics 2016; 11(2): 110-119. Abstract
  4. Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert AS, Wang Q, Imbusch CD, Serva A, Koser SD, Brocks D, Lipka DB, Bogatyrova O, Weichenhan D, Brors B, Rassenti L, Kipps TJ, Mertens D, Zapatka M, Lichter P, Dohner H, Kuppers R, Zenz T, Stilgenbauer S, Byrd JC, Plass C. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet 2016; 48(3): 253-264. Abstract

2015

  1. Schnöder TM, Arreba-Tutusaus P, Griehl I, Bullinger L, Buschbeck M, Lane SW, Döhner K, Plass C, Lipka DB*, Heidel FH*, Fischer T*. (* Co-senior author) Epo-induced erythroid maturation is dependent on Plcy1 signaling. Cell Death Differ. 2015; 22(6): 974-985
  2. Ohrnberger S, Thavamani A, Braeuning A, Lipka DB, Kirilov M, Geffers R, Authenrieth SE, Römer M, Zell A, Bonin M, Schwarz M, Schütz G, Schirmacher P, Plass C, Longerich T, Nordheim A. Dysregulated SRF triggers formation of hepatocellular carcinoma. Hepatology 2015; 61(3): 979-989

2014

  1. Lipka DB*, Wang Q*, Cabezas-Wallscheid N*, Klimmeck D*, Weichenhan D, Herrmann C, Lier A, Brocks D, von Paleske L, Renders S, Wünsche P, Zeisberger P, Gu L, Haas S, Essers MAG, Brors B, Eils R, Trumpp A, Milsom MD, Plass C. (* Co-first author) Identification of DNA methylation changes at cis-regulatory elements during early steps of HSC differentiation using tagmentation-based whole genome bisulfite sequencing. Cell Cycle 2014; 13(22): 3476-3487.
  2. Cabezas-Wallscheid N*, Klimmeck D*, Hansson J*, Lipka DB*, Reyes A*, Wang Q, Weichenhan D, Lier A, von Paleske L, Renders S, Wünsche P, Zeisberger P, Brocks D, Gu L, Herrmann C, Haas S, Essers MA, Brors B, Eils R, Huber W, Milsom MD, Plass C, Krijgsveld J, Trumpp A. (* Co-first author). Identification of regulatory networks in HSCs and their immediate progeny via integrated proteome, transcriptome, and DNA Methylome analysis. Cell Stem Cell 2014; 15(4): 507-522.
  3. Brocks D, Assenov Y, Minner S, Bogatyrova O, Simon R, Koop C, Oakes C, Zucknick M, Lipka DB, Weischenfeldt J, Feuerbach L, Cowper-Sal.lari R, Lupien M, Brors B, Korbel J, Schlomm T, Tanay A, Sauter G, Gerhäuser C, Plass C. Intratumor DNA Methylation Heterogeneity Reflects Clonal Evolution in Aggressive Prostate Cancer. Cell Reports 2014; 8(3):798-806.
  4. Poetsch AR, Lipka DB, Witte T, Claus R, Nöllke P, Zucknick M, Olk-Batz C, Fluhr S, Dworzak M, De Moerloose B, Starý J, Zecca M, Hasle H, Schmugge M, van den Heuvel-Eibrink MM, Locatelli F, Niemeyer CM, Flotho C, Plass C. RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia. Epigenetics 2014; 9(9):1252-1260.
  5. Wolleschak D, Mack TS, Perner F, Frey S, Schnöder TM, Wagner MC, Höding C, Pils MC, Parkner A, Kliche S, Schraven B, Hebel K, Brunner-Weinzierl M, Ranjan S, Isermann B, Lipka DB, Fischer T, Heidel FH. Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function. Haematologica 2014;99(6):e90-3.
  6. Sonnet M, Claus R, Becker N, Zucknick M, Petersen J, Lipka DB, Oakes CC, Andrulis M, Lier A, Milsom MD, Witte T, Gu L, Kim-Wanner SZ, Schirmacher P, Wulfert M, Gattermann N, Lübbert M, Rosenbauer F, Rehli M, Bullinger L, Weichenhan D, Plass C. Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia. Genome Medicine 2014;6(4):34.

2013

  1. Lipka DB, Kuck D, Kliem C and Gerhauser C. Substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes: a patent evaluation (WO2012075381). Expert Opin Ther Pat 2013;23(4): 537-543.
  2. Wagner MC, Dziadosz M, Melo JV, Heidel F, Fischer T, Lipka DB. Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells. Leukemia 2013 Jul;27(7):1567-70. doi: 10.1038/leu.2012.364. Epub 2012 Dec 12

2012

  1. Dziadosz M, Wagner M-C, Lipka DB, Fischer T, Bartels H. High-performance liquid chromatography with ultraviolet detection and protein precipitation as a way of quantitative determination of nilotinib with and without internal standard. Journal of Liquid Chromatography & Related Technologies 2012. 10.1080/10826076.2011.636469.
  2. Lipka DB, Wagner MC, Dziadosz M, Schnöder T, Heidel F, Schemionek M, Melo JV, Kindler T, Müller-Tidow C, Koschmieder S, Fischer T. Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to Apoptosis in CML Cells. PLoS ONE 2012, doi 10.1371/journal.pone.0040853
  3. Heidel FH, Mack TS, Razumovskaya E, Blum MC, Lipka DB, Ballaschk A, Kramb JP, Plutizki S, Rönnstrand L, Dannhardt G, Fischer T. 3,4-Diarylmaleimides-a novel class of kinase inhibitors-effectively induce apoptosis in FLT3-ITD-dependent cells. Ann Hematol. 2012; 91(3):331-344. doi: 10.1007/s00277-011-1311-3. Epub 2011 Sep 1. (PMID: 21881825)

2010

  1. Markova B, Albers C, Breitenbücher F, Melo JV, Brümmendorf TH, Heidel F, Lipka D, Duyster J, Huber C, Fischer T. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma driven activation of mTOR/p70S6-kinase pathway. Oncogene 2010; 29(5): 739-751
  2. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010; 116(24): 5089-5102.

2009

  1. Kreft A, Springer E, Lipka DB, Kirkpatrick CJ. Wild-Type JAK2 Secondary Acute Erythroleukemia Developing after JAK2-V617F-Mutated Primary Myelofibrosis. Acta Haematologica 2009; 122:36-38.
  2. Heidel F, Lipka DB, Mirea FK, Mahboobi S, Grundler R, Kancha RK, Duyster J, Huber C, Böhmer FD, Fischer T. Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro. Br. J. Hematol. 2009; 144(6): 865-874.

2008

  1. Kasper S, Breitenbuecher F, Hoehn Y, Heidel F, Lipka DB, Markova B, Huber C, Kindler T, Fischer T. The kinase inhibitor LS104 induces apoptosis enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Leuk Res 2008, 32(11): 1698-1708.
  2. Lipka D*, Heidel F*, Huber C, Fischer T. (*diese Autoren trugen gleichermaßen zum Artikel bei) Entwicklung und Anwendung von Tyrosinkinaseinhibitoren bei hämatologischen Neoplasien – FLT3 und JAK2 als therapeutisches Target bei akuter myeloischer Leukämie (AML) und myeloproliferativen Syndromen (cMPD). Pharm Unserer Zeit 2008; 37(5): 394-403.
  3. Lipka DB, Hoffmann LS, Heidel F, Markova B, Blum MC, Breitenbuecher F, Kasper S, Kindler T, Levine RL, Huber C, Fischer T. LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Mol Cancer Ther 2008; 7(5): 1176-1184.

to top